Form 4: Beam Therapeutics Executive Receives RSUs

Giuseppe Ciaramella, President of Beam Therapeutics Inc., was granted 40,000 restricted stock units (RSUs) on March 31, 2026.

Summary

• Giuseppe Ciaramella, President of Beam Therapeutics Inc., received a grant of 40,000 restricted stock units (RSUs) on March 31, 2026.
• These RSUs are part of the company's 2019 Equity Incentive Plan.
• Each RSU represents the right to receive one share of Beam Therapeutics' common stock.
• The RSUs will vest in four equal installments over the first four anniversaries of the grant date, contingent upon continued employment.
• Following the transaction, Ciaramella beneficially owns 230,216 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant financial or strategic development.

Positives

• Grant of 40,000 RSUs to a key executive, indicating continued investment in leadership and potential future value.
• The RSUs are subject to vesting over four years, aligning executive incentives with long-term company performance.
• The executive's beneficial ownership of 230,216 shares indicates a significant personal stake in the company's success.

Risks

• Vesting of RSUs is contingent on continued service, meaning potential forfeiture if the executive leaves the company before vesting dates.
• The value of the RSUs is tied to the future performance of Beam Therapeutics' stock, which is subject to market volatility and company-specific risks.

Future Outlook

The RSUs are set to vest over four years, contingent on continued service, suggesting a long-term outlook for the executive's role and commitment to the company.

Industry Context

StockSavvy.ai notes that grants of restricted stock units to executives are a common practice in the biotechnology and pharmaceutical sectors, used to attract, retain, and incentivize key talent by aligning their financial interests with the long-term success of the company.

Stakeholder Impact

• Shareholders: The RSU grant is a form of compensation, which can impact dilution if shares are issued upon vesting. However, it also aligns executive interests with shareholder value.
• Employees: The RSU grant is part of the company's broader equity incentive strategy, which may influence employee morale and retention.
• Management: The grant reinforces the executive's role and commitment to the company's long-term objectives.

Next Steps

• Vesting of RSUs in four equal installments over the next four years, subject to continued service.

Key Dates

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Trading, Restricted Stock Units, RSUs, Equity Incentive Plan, Executive Compensation, Securities Ownership